© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
DexCom, Inc. (DXCM) stock surged +0.64%, trading at $75.25 on NASDAQ, up from the previous close of $74.77. The stock opened at $74.94, fluctuating between $74.04 and $76.03 in the recent session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Jun 11, 2026 | 74.85 | 76.03 | 74.04 | 75.25 | 6.56M |
| Jun 10, 2026 | 78.82 | 78.91 | 74.64 | 74.77 | 4.78M |
| Jun 09, 2026 | 77.48 | 78.82 | 76.50 | 78.19 | 5.17M |
| Jun 08, 2026 | 73.91 | 78.52 | 73.00 | 76.62 | 7.45M |
| Jun 05, 2026 | 73.47 | 75.44 | 72.52 | 72.86 | 4.67M |
| Jun 04, 2026 | 74.13 | 74.92 | 71.53 | 72.59 | 6.14M |
| Jun 03, 2026 | 73.00 | 73.25 | 71.95 | 72.77 | 4M |
| Jun 01, 2026 | 73.49 | 76.35 | 72.50 | 74.87 | 6.14M |
| May 29, 2026 | 72.89 | 73.83 | 72.50 | 73.74 | 9.26M |
| May 28, 2026 | 70.11 | 72.76 | 69.60 | 72.34 | 5.62M |
| May 27, 2026 | 72.53 | 72.65 | 69.92 | 70.26 | 5.86M |
| May 26, 2026 | 72.02 | 73.10 | 70.14 | 72.01 | 5.31M |
| May 22, 2026 | 71.90 | 73.05 | 71.31 | 72.10 | 6.73M |
| May 21, 2026 | 71.50 | 72.27 | 70.18 | 71.90 | 9.08M |
| May 20, 2026 | 66.71 | 71.48 | 66.30 | 71.44 | 11.2M |
| May 19, 2026 | 65.28 | 67.75 | 64.47 | 66.95 | 11.3M |
| May 18, 2026 | 61.79 | 65.17 | 61.54 | 65.09 | 13.51M |
| May 15, 2026 | 59.91 | 63.19 | 59.46 | 61.63 | 11.13M |
| May 14, 2026 | 59.02 | 59.56 | 57.66 | 57.82 | 4.31M |
| May 13, 2026 | 60.45 | 61.36 | 58.53 | 58.57 | 7M |
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company's products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
| Employees | 10200 |
| Beta | 1.56 |
| Sales or Revenue | $3.62B |
| 5Y Sales Change% | 2.209% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Medical - Devices |